Novo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide ...

Glenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...

Eli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...

Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new prod...

Eli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outre...

Indian markets saw volatility and closed lower on Wednesday. Analysts are watching key support levels. Several companies are in focus due t...

Cipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...

Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...

At a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...

Mounjaro has made a splash in Indian healthcare, emerging as the go-to solution for both diabetes management and weight loss. This remarkab...

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under ...

In an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...